Ziekenhuis Oost-Limburg
Genk, 3600, Belgium
NCT Number: NCT04234984
Management of chronic knee pain remains a challenge to the treating physician. A radiofrequency treatment of the genicular nerves is a not yet established but promising technique. This procedure is minimal invasive and has few adverse events. For these reasons it can be advantageous and fulfilling the unmet needs of these chronic knee pain patients warranting further research of its efficacy.
To investigate this efficacy, all patients treated with radiofrequency ablation in the multidisciplinary chronic pain center between 1 September 2017 and 31 December 2019 with exclusion of patients with chronic widespread pain, will be retrospectively analyzed in a single-center cohort.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Genk, 3600, Belgium
This project has as primary objective the evaluation of treatment success of a conventional radiofrequency treatment of the genicular nerves in patients diagnosed with chronic knee pain due to osteoarthritis of the knee or persistent post-surgical pain (PPSP) at six weeks post treatment. Secondary objectives are evaluation of treatment effect at a third time point at the end of the inclusion period, subgroup analysis of treatment success based on indication to treatment, evaluation of subjective functional improvement and change in analgesics, estimation of the duration of effect of the treatment and adverse events.
This study includes all patients treated with radiofrequency ablation in the multidisciplinary chronic pain center in Ziekenhuis Oost-Limburg, Campus Sint-Barbara between 1 September 2017 and 31 December 2019 with exclusion of patients with chronic widespread pain.
The main study outcome is the proportion of patients with a global perceived effect of at least 50% at 6 weeks post intervention. Secondary outcomes include reduction in pain intensity, measured by Numeric Rating Scale (NRS) at six weeks and at a third time point, global perceived effect at a third time point, subjective change in physical functioning, duration effect of the treatment, use of strong opioids, and adverse events.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 weeks after treatment
Treatment success is defined as a global perceived effect (GPE) of at least 50% at measurement time point compared to baseline.
Global perceived effect (GPE) scales are used as an overall outcome measure for patients with pain, as they may cover additional aspects to pain relief and physical function that are important to the individual. Patients are asked to response on the question of how the treatment influenced the pain symptoms. The patients were asked to expres their answer in percentage where 0 % ( no improvement) to 100 (total improvement, the symptoms are gone).
Time frame: 6 weeks after treatment
The numeric rating scale (NRS) is used to assess pain intensity varying from 0 (no pain) to 10 (intense pain). This scale was retrieved retrospectively out of the patient file.
NRS reduction ≥50% is calculated using the NRS at 6 weeks compared to the NRS at baseline.
Time frame: after retrieval of informed consent, ranging from 6 weeks to 2.5 years after the procedure
The numeric rating scale (NRS) is used to assess pain intensity varying from 0 (no pain) to 10 (intense pain). This scale will be asked telephonically to the patient.
Time frame: after retrieval of informed consent, ranging from 6 weeks to 2.5 years after the procedure
The question 'Do you experience at the moment functional improvement in comparison with before the treatment?' is asked telephonically to the patient. The possible answers are 'no increase in physical functioning' and ' yes, there was an increase in physical funcitoning'. An increase in physical functioning is the best outcome.
Time frame: 6 weeks after treatment
The change in use of strong opioids is retrieved retrospectively out of the patient file. The answer to the use of strong opioids is yes or no. No use of strong opioids is a better outcome.
Time frame: after retrieval of informed consent, ranging from 6 weeks to 2.5 years after the procedure
The change in use of strong opioids is asked telephonically to the patient.
Time frame: after retrieval of informed consent, ranging from 6 weeks to 2.5 years after the procedure
Treatment success is defined as a global perceived effect (GPE) of at least 50% at measurement time point compared to baseline.
Global perceived effect (GPE) scales are used as an overall outcome measure for patients with pain, as they may cover additional aspects to pain relief and physical function that are important to the individual. Patients are asked to response on the question of how the treatment influenced the pain symptoms. The patients were asked to expres their answer in percentage where 0 % ( no improvement) to 100 (total improvement, the symptoms are gone).
Time frame: 6 weeks after treatment.
Adverse events related to the conventional radiofrequency therapy will be assessed. This will be assessed retrospectively in the patient file according to the standard of care consultation at 6 weeks after treatment.
Time frame: after retrieval of informed consent, ranging from 6 weeks to 2.5 years after the procedure
Adverse events related to the conventional radiofrequency therapy will be assessed telephonically
Ziekenhuis Oost-Limburg
Other
A Retrospective Single-center Cohort Study on Patients With Chronic Knee Pain Treated With Conventional Radiofrequency of the Genicular Nerves
Acronym: RECORGEN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06505681
Chronic Knee Pain
Daejeon, South Korea
View Trial DetailsNCT07125768
Advanced Knee Osteoarthritis, Alcoholic Neurolysis
Tanta, El-Gharbia, Egypt
View Trial DetailsNCT06554483
Chronic Knee Pain, Chronic Pain
Muş, Turkey (Türkiye)
View Trial DetailsNCT05003323
Agnosia, Analgesia
Pittsburgh, Pennsylvania, United States
View Trial Details